Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02159495 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02159495 · ClinicalTrials.gov record · last posted 2026-08-26

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

StatusActive, Not Recruiting
PhasePhase 1
Started2015-12-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm that has returned after a period of improvement or has not responded to previous treatment. An immune cell is a type of blood cell that can recognize and kill abnormal cells in the body. The immune cell product will be made from patient or patient's donor (related or unrelated) blood cells. The immune cells are changed by inserting additional pieces of deoxyribonucleic acid (DNA) (genetic material) into the cell to make it recognize and kill cancer cells. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

Protocol amendment history 2 changes detected by DataLookout

2026-08-27
Primary completion pushed: 2026-08-06 → 2027-07-14
2026-08-27
Completion pushed: 2026-08-06 → 2027-07-14
Trial Details
NCT Number NCT02159495
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI), Mustang Bio, Inc.
Conditions Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia +5 more
Enrollment 31 participants
Start Date 2015-12-15
Primary Completion 2027-07-14 (estimated)
Study Completion 2027-07-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-26